

Risankizumab for treating moderately to severely active ulcerative colitis

Technology appraisal guidance

Published: 22 August 2024

www.nice.org.uk/guidance/ta998

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the [Yellow Card Scheme](#).

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations](#) wherever possible.

Contents

1 Recommendations	4
2 Information about risankizumab	6
Marketing authorisation indication	6
Dosage in the marketing authorisation	6
Price.....	6
3 Implementation.....	7
4 Evaluation committee members and NICE project team.....	8
Evaluation committee members	8
Chair	8
NICE project team	8

1 Recommendations

- 1.1 Risankizumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or has lost response to treatment, only if:
- a tumour necrosis factor (TNF)-alpha inhibitor:
 - has not worked (that is the condition has not responded well enough or has lost response to treatment), or
 - cannot be tolerated or is not suitable, and
 - the company provides it according to the [commercial arrangement](#).
- 1.2 If people with the condition and their clinicians consider risankizumab to be 1 of a range of suitable treatments (including ustekinumab), after discussing the advantages and disadvantages of all the options, use the least expensive. Take into account the administration costs, dosage, price per dose and commercial arrangements.
- 1.3 These recommendations are not intended to affect treatment with risankizumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Why these recommendations were made

TNF-alpha inhibitors are the most used biological treatments for moderately to severely active ulcerative colitis. When TNF-alpha inhibitors have not worked, or are not tolerated, one of the treatment options is ustekinumab. Risankizumab works in a similar way to ustekinumab and would be offered to the same population.

Clinical trial evidence shows that risankizumab is more effective than placebo for treating moderately to severely active ulcerative colitis. Risankizumab has not been directly compared with ustekinumab in a clinical trial in this population. But an indirect comparison

suggests that it is similarly effective.

A cost comparison suggests risankizumab has similar costs to ustekinumab. Using [NICE's cost-comparison methods](#), risankizumab only needs to cost less or have similar costs to 1 relevant comparator to be recommended as a treatment option. So risankizumab is recommended.

For all evidence see the [committee papers](#). To see how NICE evaluated ustekinumab refer to the committee discussion section in [NICE's technology appraisal guidance on ustekinumab for treating moderately to severely active ulcerative colitis](#).

2 Information about risankizumab

Marketing authorisation indication

- 2.1 Risankizumab (Skyrizi, AbbVie) is indicated 'for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy'.

Dosage in the marketing authorisation

- 2.2 The dosage schedule is available in the summary of product characteristics for risankizumab.

Price

- 2.3 The list price of risankizumab is £3,326.09 per:
- 600 mg vial of concentrate for solution for intravenous infusion (excluding VAT; BNF online accessed July 2024)
 - 360 mg doses of solution for injection for subcutaneous administration (excluding VAT; BNF online accessed July 2024)
 - 180 mg doses of solution for injection for subcutaneous administration (excluding VAT; provisional).
- 2.4 The company has a [commercial arrangement](#). This makes risankizumab available to the NHS with a discount. The size of the discount is commercial in confidence.

3 Implementation

- 3.1 Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care boards, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this evaluation within 3 months of its date of publication. Because risankizumab has been recommended through the cost-comparison process, NHS England and integrated care boards have agreed to provide funding to implement this guidance 30 days after publication.
- 3.2 The Welsh ministers have issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal guidance recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the final draft guidance.
- 3.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has moderately to severely active ulcerative colitis and the doctor responsible for their care thinks that risankizumab is the right treatment, it should be available for use, in line with NICE's recommendations.

4 Evaluation committee members and NICE project team

Evaluation committee members

This topic was considered by the chair and vice chair of NICE's highly specialised technologies evaluation committee.

Committee members are asked to declare any interests in the technology being evaluated. If it is considered there is a conflict of interest, the member is excluded from participating further in that evaluation.

Chair

Paul Arundel

Chair, highly specialised technologies evaluation committee

NICE project team

Each evaluation is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the evaluation), a technical adviser and a project manager.

Alex Sampson

Technical lead

Zoe Charles

Technical adviser

Jeremy Powell

Project manager

ISBN: 978-1-4731-6210-5